Lineage Cell Therapeutics, Inc.
AMEX: LCTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Culley
- Employees
- 75
- Headquarters
- Carlsbad, United States
- IPO year
- 1992
- Market cap
- $324.1M
- Website
- https://www.lineagecell.com
Loading LCTX…
Loading profile data…Frequently asked questions about LCTX
What does Lineage Cell Therapeutics, Inc. (LCTX) do?
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the...
Where does LCTX trade?
Lineage Cell Therapeutics, Inc. (LCTX) trades on the New York Stock Exchange Arca.
What sector is LCTX in?
Lineage Cell Therapeutics, Inc. (LCTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lineage Cell Therapeutics, Inc.?
Brian Culley is the chief executive officer of Lineage Cell Therapeutics, Inc. (LCTX).
Where is Lineage Cell Therapeutics, Inc. headquartered?
Lineage Cell Therapeutics, Inc. is headquartered in United States.
Does LCTX pay a dividend?
Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LCTX go public?
Lineage Cell Therapeutics, Inc. (LCTX) completed its initial public offering in 1992.